Highest-materiality recent filing
FDA approves Afrezza for pediatric diabetes patients ages 6+
FDA approved supplemental BLA for Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.
FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29
FDA informed MannKind on May 27, 2026 it is released from postmarketing requirement to assess pulmonary malignancy risk in 8,000-10,000 patients.
MannKind Q1 total revenue $90.2M (+15% YoY); Furoscix adds $15.5M; cash $134M
Total revenue $90.2M (+15% YoY); royalties from Tyvaso DPI up 9% to $32.7M.
MannKind Q4 revenue $112M (+46% YoY); Furoscix adds $23M in first quarter
Total revenues $112M in Q4 2025, up 46% vs Q4 2024; full-year revenues $349M, up 22%.
MannKind pro forma shows $36.1M net loss for H1 2025 post-scPharma acquisition
Acquired scPharma for $5.35/share cash plus CVR (up to $1.00/share); total consideration $396.4M cash.
MannKind discontinues Phase 3 MNKD-101 trial for NTM lung disease after futility analysis
Discontinuation based on interim analysis of first 46 participants; none showed sputum culture conversion.
MannKind Q3 revenue $82.1M (+17% YoY); completes scPharma acquisition
Q3 2025 revenues $82.1M (+17% YoY); YTD revenues $237.0M (+14%).
MannKind completes $296.5M acquisition of scPharmaceuticals; funds with $250M debt
Tender offer expired Oct 6 with 73.47% shares tendered; merger closed Oct 7, 2025; scPharma becomes wholly owned subsidiary.
MannKind receives $5M upfront from United Therapeutics for new product option exercise
MannKind entered First Amendment with United Therapeutics to exercise option for an additional development product using its Technosphere platform.
MannKind to acquire scPharmaceuticals for $5.35/share plus CVR up to $1.00/share
Offer price: $5.35 cash + one contingent value right (CVR) per share; CVR milestones up to $1.00 aggregate.
MannKind Q2 revenue $76.5M (+6% YoY); Afrezza sBLA for pediatric population submitted
Total revenues $76.5M, up 6% YoY; net income $0.7M versus net loss $2.0M in Q2 2024.
MannKind Q1 revenue $78M (+18% YoY); net income $13.2M (+24%)
1Q25 revenue $78.4M (+18% YoY); GAAP net income $13.2M (+24%); non-GAAP net income $21.6M (+43%).
MannKind reports 2024 revenue of $286M, net income of $28M; debt reduced by $236M
Full year 2024 revenue $286M (+43% YoY); Q4 revenue $77M (+31% YoY).
MannKind exchanges $193.7M of 2.50% convertible notes for 26.7M shares plus $89.2M cash
Aggregate principal $193.7M of 2.50% Convertible Senior Notes due 2026 exchanged for 26,749,559 shares of common stock.
MannKind Q3 total revenue $70M (+37% YoY); YTD net income $20M, non-GAAP $45M
Q3 total revenue $70.1M (+37% YoY); YTD revenue $208.7M (+49% YoY); YTD net income $20M.
MannKind Q2 revenue $72M (+49% YoY), net income $9M YTD; pipeline advances
Q2 total revenues $72.4M, up 49% vs. $48.6M in Q2 2023; YTD revenues $138.6M, up 55%.
MannKind Q1 revenue $66M (+63% YoY); net income $11M; FDA Fast Track for MNKD-101
Total revenues $66.3M (+63% YoY); GAAP net income $11M; non-GAAP net income $15M.
On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.
the board of directors of the Company appointed Ms. Sabella as Executive Vice President, Operations, effective January 6, 2025.
On January 2, 2025, Lauren Sabella notified us of her intention to retire from MannKind Corporation (the “Company”), effective July 18, 2025
His employment will end concurrently with his appointment to the Board on the Effective Date.
On August 13, 2024, the Board approved the appointment of Steven B. Binder to the Board, effective on the Effective Date.
On August 13, 2024, Kent Kresa notified us of his decision to retire from our Board of Directors (the “Board”), effective September 30, 2024 (the “Effective Date”).
Max materiality 0.90 · Median 0.75 · Most common event earnings